[Use of a thymus polypeptide preparation to diagnose and correct immune deficiency states in multiple sclerosis].
Golovkin. V I VI; Ankhimova. E S ES; Morozov. V G VG; Khavinson. V G VG
Key Findings
- Thymalin was tested for the first time as a treatment for multiple sclerosis
- Patients showed positive clinical and immunological responses
- The peptide affected T‑cell sensitivity to immune challenges and steroids
Practical Outcomes
- The results hint that thymalin could be explored as an immune‑modulating supplement, but the study is tiny and specific to MS. Biohackers should treat it as experimental, watch for more research, and be cautious about dosing or using it for general health benefits.
Summary
A small study gave a calf‑thymus peptide called thymalin to 36 people with multiple sclerosis and saw some improvements in symptoms and immune markers, suggesting it might help modulate the immune system in this disease.
Abstract
Thymus-dependent immunity as well as thymic factor and corticosteroid influence upon it were studied in 36 patients with disseminated sclerosis. The illness was diagnosed according to the Poser system with the help of the spontaneous erythrocyte rosette test. The sensitivity of T lymphocytes to thymaline, to basic myelin protein and to prednisolone was analyzed. The Soviet drug thymaline, obtained from calf thymus, was first used for the treatment of disseminated sclerosis. Clinical and immunological results turned out positive. The possibility of differential immunomodulating therapy of disseminated sclerosis is shown.
Study Information
pubmed
1984